BioCryst Pharmaceuticals, Inc.

Good morning and welcome to the Biochrist fourth quarter 2024 earnings call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to John Bluth at Biochrist. Please go ahead.

Thanks, Drew. Good morning and welcome to Biochrist's fourth quarter 2024 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO John Stonehouse, CFO Anthony Doyle, Chief Commercial Officer Charlie Geyer, and Chief R&D Officer Dr. Helen Thackeray. Following our remarks, we'll answer your questions. Today's conference call will contain forward-looking statements, including those statements regarding future results on audited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause their actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company documents followed with the Securities and Exchange Commission, which can be accessed on our website. In addition, today's conference call includes non-GAAP financial measures. For reconciliation of these non-GAAP measures against the most directly comparable GAAP financial measure, please refer to the earnings release posted in the press releases section of our investor relations website at www.biocrist.com. Now I'd like to turn the call over to John Stonehouse.

Thank you, John. We ended 2024 with the strongest execution and performance in the company's history. What's even more exciting is it happened across the company. For the full year 2024, Orladeo revenue year over year grew by 34%, and we added as many patients as we did in the first year of launch. This is an amazing result for a rare disease medicine, especially considering it came in the fourth year on the market and reflects excellent execution by the commercial team. Next, on the clinical front, we now have the data from our pediatric clinical trial with Orladeo to put us in a position to file the NDA this year. We also advanced BCX17725 for Netherton syndrome into the clinic and made progress with the Wurlstat for DME that will enable us to put that program into the clinic this year. All of these advancing programs represent an opportunity to serve patients and provide them something meaningfully better than is currently available to them, a chance to really change their life. Whether it's no longer having to inject your toddler with their medicine for HAE, finally having a treatment to change the underlying cause of Netherton syndrome, or giving DMA patients hope of a new therapy that may work for more patients and be given with fewer injections. The execution of our teams last year has put us in a great position to get data and answers on these programs later this year. And finally, we executed so well last year that we not only generated a non-GAAP operating profit, but this profit was over $60 million, which is three times larger than what we had planned. The magnitude of the free cash flow we now expect over the next three years will likely further transform our company. The place we find ourselves in today was intentional, as the execution by the employees at Biochrist has never been better, and the momentum we have is carrying over to this year and likely many years to come. I'll now turn it over to Charlie.